AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Statin no better than usual care in reducing risk of morbidity, mortality.

Biotech Week

| January 08, 2003 | COPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2003 JAN 8 - (NewsRx.com & NewsRx.net) -- Pravastatin, a statin drug used to reduce cholesterol, does not reduce the death rate or incidence of coronary heart disease events in patients with moderately high cholesterol and well-controlled high blood pressure, when compared to usual care, according to researchers in Texas and Washington.

The role levels of low-density lipoprotein cholesterol (LDL-C, the "bad" cholesterol) play in the development of coronary heart disease (CHD) is well-established. Trials in the 1970s and 1980s showed that lowering LDL-C reduced the incidence of CHD-related events such as heart attack, but the average reduction in LDL-C for these trials was only 10%.

In the 1980s, a more powerful class of drugs, statins, were developed which could reduce total cholesterol by approximately 20% or more. Studies have demonstrated that statins administered to individuals with risk factors for CHD reduce CHD events. However, many of these studies were too small to assess all-cause mortality or outcomes in important subgroups.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) evaluated the impact of sustained cholesterol reductions on deaths in an older population with high blood pressure and moderately high cholesterol with at least one other CHD risk factor using pravastatin in all patients vs. usual care, which could include lowering cholesterol using statins if the patient's physician chose to prescribe it.

ALLHAT-LLT was a randomized, nonblinded trial conducted from February 1994 through March 2002 at 513 North American clinical centers. Jeffrey L. Probstfield, MD, of the University of Washington Medical Center, Seattle, and Barry R. Davis, MD, PhD, from the University of Texas - Houston Health Science Center, and colleagues enrolled 10,355 people aged 55 or older with high LDL-C levels (120-180 mg/dL) in their study.

All participants were also enrolled in ALLHAT, a study comparing treatments to lower blood pressure. The average age of the participants was 66 years, 49% were women, 38% black, and 23% Hispanic. Fourteen percent had a history of CHD and 35% of participants had type 2 diabetes. Of the participants, 5170 were assigned to the pravastatin group (40 mg/day) and 5185 were assigned to usual care.

Results were reported in the December 18, 2002, issue of the Journal of the American Medical Association.

Related articles from newspapers, magazines, journals, and more
GenoMed Announces ALLHAT Study is Fatally Flawed.
Press release article from: PR Newswire December 18, 2002 700+ words
...genomics company, announced today that the ALLHAT study published in today's Journal of...Association has a fatal research flaw. ALLHAT, an 8 year study funded by the National...only 50% of the enzyme activity. The ALLHAT investigators should have used one of...
Data challenged; ALLHAT study is flawed, PI says.
Newspaper article from: Biotech Week January 29, 2003 700+ words
...GenoMed, Inc., announced that the ALLHAT study published in a recent issue of Journal...Association has a fatal research flaw. ALLHAT, an 8-year study funded by the National...only 50% of the enzyme activity. The ALLHAT investigators should have used one of...
Conclusions of ALLHAT Study questioned.
Newspaper article from: Drug Week February 20, 2004 700+ words
...conclusions being drawn from the results of the ALLHAT study? "The Antihypertensive and Lipid...Treatment to Prevent Heart Attack Trial (ALLHAT) Study, the largest double-blind...University of Pisa. "Moreover, the ALLHAT study has other limitations, and its...
ALLHAT study recommends diuretics; Dyrenium reduces side effects.
Newspaper article from: Biotech Week January 22, 2003 700+ words
...Corporation commented on findings of the ALLHAT hypertension study, the National Institutes...diuretics, including those used in the ALLHAT study, to prevent some of these side...potassium supplements. The results of ALLHAT - a 5-year, 42,000-patient mortality...
ALLHAT Study Highly Recommends Diuretics for Hypertension; WellSpring's...
Press release article from: PR Newswire December 17, 2002 700+ words
...Corporation today commented on findings of the ALLHAT hypertension study, the National Institutes...diuretics, including those used in the ALLHAT study, to prevent some of these side...potassium supplements. The results of ALLHAT -- a 5-year, 42,000-patient mortality...
FDA Panel Says ALLHAT Findings On Doxazosin Should Be Issued.(Antihypertensive...
Magazine article from: Internal Medicine News MECHCATIE, ELIZABETH July 1, 2001 700+ words
...and Renal Drugs Advisory Committee. The ALLHAT arm that compared the [alpha]-blocker...currently labeled," the company said. ALLHAT is an ongoing, practice-based, multicenter...information on the doxazosin doses used in ALLHAT. Also, the diagnosis of CHF was questioned...
Recently Reported ALLHAT Trial Does Not Address Benefits of Altace; Altace...
Press release article from: PR Newswire December 19, 2002 700+ words
...Treatment to Prevent Heart Attack Trial ("ALLHAT"), but was the subject of the landmark...Prevention Evaluation) trial. Rather, the ALLHAT trial involved patients who were treated...sales of Altace(R). In contrast, the ALLHAT trial compared certain blood pressure...
Norvasc ALLHAT review cancelled.(Noted)
Magazine article from: Pharmaceutical Processing April 1, 2005 700+ words
Norvasc ALLHAT review cancelled: FDA's Cardiovascular & Renal Drugs April 5 review of supplemental indications for Pfizer's Norvasc based on the results of the Antihypertensive & Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) has been cancelled.
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA